You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Evaluation of TRB-N0224, a Proprietary Chemically-Modified Curumin, for the Treat
SBC: TRAVERSE BIOSCIENCES, INC. Topic: NIADESCRIPTION (provided by applicant): Traverse Biosciences Inc. is a pre-clinical stage drug development company working to commercialize new chemical entities which act to resolve inflammatory conditions through pleiotropic host-modulation of pathologically unrestrained matrix metalloproteinases (MMPs) and pro-inflammatory cytokines. The company's lead drug candidate, TRB-N0224, is a proprie ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Expanding teleconsent capabilities to improve clinical research recruitment
SBC: Doxy.me Inc. Topic: NLMLack of recruitment of qualified research participants into clinical trials remains to be one of the most important issues in clinical research Studies often struggle to meet recruitment goals on time resulting in costly time extensions underpowered results and in some cases early termination Many reasons attribute to suboptimal recruitment including the challenges related to informing and c ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
F10: a novel therapeutic to treat refractory or relapsed AML
SBC: SOUTHEAST TECHINVENTURES INC Topic: NCIDESCRIPTION (provided by applicant): Acute myeloid leukemia (AML) affected ~14,600 new patients in 2013 in the US and caused over 10,000 deaths, primarily in older adults. The current chemotherapy regimen, a combination of cytarabine (AraC) and anthracyclines such as daunorubicin (DNR), has resulted in 5-year survival rates of only 30-40% (less than 10% in patients over 60 years old). The principa ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Flexible Ion-Mediated Artificial Retina
SBC: LAMBDAVISION INCORPORATED Topic: NEIDESCRIPTION (provided by applicant): A flexible, protein-based, ion-mediated retinal implant is proposed for the restoration of vision for patients with retinal degenerative diseases, such as age-related macular degeneration (AMD) and retinitis pigmentosa(RP). The implant under development uses the retinal- containing protein, bacteriorhodopsin (BR), to convert light into a pH gradient. This gradi ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Functional-selection of affinity reagents against DNA-protein complexes using targeted chromatin sequences
SBC: AXIOMX INC Topic: NIDDKDESCRIPTION (provided by applicant): Site-specific binding of proteins to DNA plays an important role in cell development, cell signaling, the cell cycle, and diseases such as cancer. There are two overarching goals to this proposal: (1) to develop a meansfor the identification of proteins bound to specific DNA sequences, and (2) to develop a better method for the identification of immunoprecipita ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Geriatric Symptom Protocols for Improved Triage in Offices and Assisted Living
SBC: KEONA HEALTH, INC. Topic: NINRDESCRIPTION (provided by applicant): For medical practices, a major challenge is managing the hundreds of telephone calls received daily, many of which are about new or worsening medical symptoms. Particularly difficult are calls from persons with little or no medical training about frail older persons living at home or in assisted living (AL) communities. Incoming calls are typically answered by ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Human nasal epithelial organoids as a non-invasive, personalized model for predicting effectiveness of CFTR modulators in cystic fibrosis patients
SBC: Path BioAnalytics, Inc. Topic: ABCDESCRIPTION provided by applicant The discovery of the single gene CFTR cause of cystic fibrosis CF has been transformational focusing treatment on modulator drugs that restore function of the CFTR gene product CFTR andquot correctorsandquot enhance transport of mutant protein to the cell membrane and CFTR andquot potentiatesandquot activate mutant protein that does get to the membrane ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Image-guided planning system for skull correction in children with craniosynostos
SBC: KITWARE INC Topic: NICHDDESCRIPTION (provided by applicant): Craniosynostosis is the premature fusion of cranial sutures and occurs in approximately one in 2000 live births. It results in cranial malformation that can lead to elevated intra-cranial pressure, brain growth impairment, and developmental deficiency. The most common treatment option for craniosynostosis is surgery. Currently, surgical treatment planning of cr ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Jamboxx: Interactive Respiratory Therapy through Music and Gaming
SBC: My Music Machines Inc. Topic: NHLBIDESCRIPTION provided by applicant The goal of this project is to develop a novel device for respiratory therapy that uses interactive gaming and music to encourage patient compliance In order to maintain pulmonary health many post operative surgery patients as well as people with quadriplegia and other spinal cord injuries high level motor neuron diseases such as amyotrophic lateral sclerosi ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Live-attenuated ETEC Anti-Diarrhea Vaccine Construction via Synthetic Biology
SBC: Codagenix Inc. Topic: NIAIDDESCRIPTION provided by applicant The development of vaccine to combat Enterotoxigenic E coli ETEC is vital given the pathogenandapos s global impact on million individuals annually however an entirely new non conventional approach is needed Field studies have suggested that inert antigen based vaccines to combat ETEC have andquot essentially no efficacyandquot Therefore a vaccin ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health